Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Fibromyalgia Treatment Market to Rise at a CAGR of 3.8% during the 2024 to 2034 forecast period: Transparency Market Research

Transparency Market Research Logo

News provided by

Transparency Market Research

Jul 15, 2024, 11:00 ET

Share this article

Share toX

Share this article

Share toX

The rise in diabetic patients is a primary driver for the gastroparesis treatment market, as diabetes often leads to gastroparesis, disrupting normal digestion.

WILMINGTON, Del, July 15, 2024 /PRNewswire/ -- The global fibromyalgia treatment market stood at US$ 1.9 billion in 2023, and the global market is projected to reach US$ 2.9 billion in 2034. The fibromyalgia treatment market is anticipated to expand at a CAGR of 3.8% between 2024 and 2034.

The fibromyalgia treatment market is experiencing significant growth due to increasing awareness and diagnosis of this chronic pain disorder. Characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive issues, fibromyalgia affects millions worldwide, predominantly women. The exact cause of fibromyalgia remains unclear, but it is believed to involve a combination of genetic, environmental, and psychological factors that lead to abnormal pain processing in the brain and spinal cord.

Current treatments for fibromyalgia aim to alleviate symptoms and improve quality of life, as there is no known cure. The market comprises a diverse range of pharmacological and non-pharmacological therapies. Pharmacological treatments include analgesics, antidepressants, anticonvulsants, and muscle relaxants, which help manage pain, mood disturbances, and sleep problems. Notable medications like pregabalin, duloxetine, and milnacipran are widely prescribed and have shown efficacy in reducing fibromyalgia symptoms.

Download Sample PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22697 

Non-pharmacological treatments play a crucial role in comprehensive fibromyalgia management. Physical therapy, exercise programs, cognitive-behavioral therapy (CBT), and stress management techniques are frequently recommended to help patients cope with the condition. Lifestyle modifications, such as regular exercise, healthy diet, and adequate sleep, are also essential components of treatment plans.

The increasing prevalence of fibromyalgia, coupled with advancements in medical research, is driving innovation in this market. New therapeutic approaches, including biologics, monoclonal antibodies, and other novel drug classes, are under investigation, promising improved outcomes for patients. Moreover, the integration of digital health technologies, such as telemedicine and mobile health apps, is enhancing patient engagement and self-management, further propelling market growth.

Pharmaceutical companies are investing significantly in research and development to introduce more effective and targeted therapies. This competitive landscape is fostering collaborations and strategic partnerships aimed at accelerating the development and commercialization of innovative treatments. As awareness and understanding of fibromyalgia continue to expand, the treatment market is poised for sustained growth, offering hope for better management of this debilitating condition.Top of Form

Key Takeaways of Market Report

  • Global fibromyalgia treatment market to generate absolute dollar opportunity worth US$ 2.9 billion until 2034.
  • Global fibromyalgia treatment market is valued at US$ 1.9 billion in 2023.
  • North America is forecasted to hold the largest share in 2023.

Fibromyalgia Treatment Market: Growth Drivers Top of Form

  • According to NIAMS, nearly 5 million adults in the U.S. suffer from fibromyalgia, with over 80-90% being females. Government initiatives aim to guide healthcare professionals and manufacturers, such as the European League Against Rheumatism's 2016 recommendation against using NSAIDs for fibromyalgia treatment.
  • Key players are introducing innovative medications to maintain their market presence. For instance, Eli Lilly and Company's Galcanezumab entered its pivotal clinical end-stage in December 2021 for treating fibromyalgia, having been previously approved for cluster headache and migraine. Phase 1 data showed SP-104 treated healthy volunteers with fewer adverse events compared to immediate-release naltrexone.

Fibromyalgia Treatment Market Report Scope:

Report Coverage

Details 

Forecast Period  

2024-2034

Base Year  

2020-2022

Size in 2023

US$ 1.9 Bn

Forecast (Value) in 2034

US$ 2.9 Bn

Growth Rate (CAGR) 

3.8 %

No. of Pages 

123 Pages 

Segments covered 

By Treatment Type, By Distribution Channel, By Region

Fibromyalgia Treatment Market: Regional Landscape

  • North America dominated the fibromyalgia treatment market in 2023, a trend projected to continue due to a significant rise in patients in the U.S. grappling with fibromyalgia. Favorable reimbursement policies further bolster market growth, encouraging innovation and accessibility to advanced treatment options.
  • In Asia Pacific, the fibromyalgia treatment market is expanding, driven by improving healthcare infrastructure in countries like India and China. The region has also seen an increase in export volumes of generic drugs from manufacturers in China and India. Additionally, collaborations between international pharmaceutical giants and local companies are facilitating the introduction of new therapies, contributing to the market's development in Asia Pacific.
  • Top of Form

Request Table of Content Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=22697 

Fibromyalgia Treatment Market: Key Players

  • In 2023, Pfizer Inc. made strides in the fibromyalgia treatment market with the advancement of Tanezumab, a monoclonal antibody targeting nerve growth factor (NGF). Tanezumab showed promise in clinical trials for reducing pain associated with fibromyalgia, offering potential relief to patients who do not respond well to traditional therapies.
  • In 2023, Eli Lilly and Company continued to innovate in the fibromyalgia treatment market by progressing with their drug, Galcanezumab. Initially approved for migraine and cluster headache, Galcanezumab entered pivotal clinical trials for fibromyalgia in late 2021. Early data suggested efficacy in managing pain and improving quality of life for fibromyalgia patients, positioning it as a promising new option in the treatment landscape.

Fibromyalgia Treatment Market: Segmentation

Treatment Type

  • Medications

§  Pain Relievers

§  Anti-depressants

§  Anti-seizure Drugs

  • Therapies

§  Physical Therapy

§  Occupational Therapy

§  Counselling

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=22697&ltype=S 

Have a Look at More Valuable Insights of Healthcare:

  • AI in Endoscopy Market: According to a study published by Transparency Market Research, the global AI in Endoscopy Market is expected to advance at a compound annual growth rate of 26.9% during the forecast period between 2022 and 2031.
  • Next-Generation Sequencing Data Analysis Market: The global next-generation sequencing data analysis market stood at US$ 1.17 billion in 2022 and the global market is projected to reach US$ 5.4 billion in 2032. The next-generation sequencing data analysis market is anticipated to expand at a CAGR of 16.6% between 2022 and 2032.
  • Cuffless Blood Pressure Monitoring Devices Market: Cuffless Blood Pressure Monitoring Devices Market was valued at US$ 599.2 Mn in 2023, which is expected to grow at a CAGR of 10.8% from 2024 to 2034 and reach US$ 1.9 Bn by the end of 2034

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com   

Email: [email protected]

Follow Us: LinkedIn| Twitter| Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

SOURCE Transparency Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.